In this BCR pathway, BTK plays a major role and can be targeted by BTK inhibitors (BTKi), already used in CLL (33), MCL (30), MZL (31), Waldenström macroglobulinemia (28), and DLBCL-ABC (29). Here, BCR is linked to diffuse large B-cell lymphoma.